基石藥業(02616.HK)腫瘤藥完成中國首例受試者給藥
基石藥業(02616.HK)公布,avapritinib在正在進行的全球III期臨床試驗VOYAGER中實現首例中國受試者給藥。研究主要評估avapritinib作為三線或四線療法,相較於作為目前標準療法的瑞戈非尼對於晚期胃腸道間質瘤「GIST」患者的安全性和療效。試驗的主要研究終點是無進展生存期。
Avapritinib是一款在研的口服精准藥物,可選擇性地有效抑制KIT和PDGFRA突變激(酉每),由基石藥業合作夥伴Blueprint Medicines開發,其已向FDA(美國食藥監局)提交了新藥上市申請,有望成為基石藥業第二款在美國獲批上市的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.